EXOPULSE database for routine follow-up of balance, muscle function, and chronic pain
Official title: The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
Run by Otto Bock Healthcare Products GmbH · NCT05901259 · Data updated 2026-11-12
This registry will try the EXOPULSE Mollii and EXOPULSE suits to see if they improve balance, muscle relaxation, local circulation, and chronic pain for people with cerebral palsy, multiple sclerosis, stroke, fibromyalgia, or other neurologic conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Otto Bock Healthcare Products GmbH Industry-sponsored |
| Locations | 1 site (Bergshamra, Stockholm County) |
| Status | Recruiting |
| Started | February 18, 2026 |
| Main results expected | August 1, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 14, 2026 |
| Trial ID | NCT05901259 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 2 years or older with cerebral palsy, multiple sclerosis (diagnosed >6 months), stroke (diagnosed >6 months), fibromyalgia (diagnosed >1 month), or other neurologic disorders causing similar symptoms, who can give informed consent and follow instructions and who meet the device size and safety criteria.
✕Probably not a fit
Patients with device contraindications, recent botulinum toxin treatment (<3 months), recent medication changes affecting neuromuscular activity, extreme body sizes outside the device limits, or inability to attend on-site assessments are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational registry collecting standardized clinical data before, during, and after use of the EXOPULSE Mollii Suit and EXOPULSE Suit in people with CP, MS, stroke, fibromyalgia and related neurologic disorders. Participants serve as their own controls and the primary outcome is change in the Berg Balance Scale or Pediatric Balance Scale, with additional measures of muscle activation, relaxation, local blood flow, and chronic pain. Investigators are trained and certified in the EXOPULSE method and apply standardized stimulation settings based on age and impairment to reduce variability; assessments are unblinded because the stimulation is usually perceptible. Routine re-assessments are conducted at scheduled visits by multiple investigators to help identify high responders within diagnostic subgroups.
Why it matters
Potential benefit: If successful, the suits could reduce muscle stiffness and chronic pain, improve balance, and lower fall risk, leading to better daily function.
How similar studies have gone: Smaller case series and pilot studies of Mollii-style wearable electrical stimulation have reported improvements in spasticity, pain, and function, but robust randomized evidence is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms. * Diagnosed \>6 months prior to inclusion in case of MS or stroke as well as \>1 month prior to inclusion in the case of fibromyalgia. * Give written informed consent * Cognitively able to understand and follow verbal and/or written instructions * A minimum age of 2 years Exclusion Criteria: * Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit * Being introduced to any new medication affecting the neuromuscular activity during the study period * Using botulinum toxin \<3 month before or during the study period * Subjects \<100 cm and \<13 kg * Subjects \>205 cm and \>115 kg
Where it's running
-
Ottobock Care Sverige
Bergshamra, Stockholm County, Sweden Recruiting
Study contacts
- Principal investigator: Milana Mileusnic, PhD — Otto Bock Healthcare Products GmbH
- Study coordinator: Milana Mileusnic, PhD
- Email: milana.mileusnic@ottobock.com
- Phone: +43 6648415079
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can a powered ankle brace help people with foot drop walk faster
This study tests whether the NEUROSWING orthosis can improve walking speed in adults with dorsal and/or plantar flexor deficits compared with a carbon brace.
-
Electrical stimulation-assisted exercise for people with lower limb paralysis
This study tests whether adding electrical stimulation during exercise can improve leg muscle strength and endurance for people with paralysis.
-
Robotic upper-limb therapy with built-in cognitive exercises for people with Parkinson's, MS, or stroke
This trial will test whether sensor-based robotic arm training that includes thinking exercises can help adults with Parkinson's disease, multiple sclerosis, or stroke improve attention, memory, and arm movement.
-
Mollii neuromodulation suit to improve function and quality of life after stroke or multiple sclerosis
This trial will test whether wearing the Mollii neuromodulation suit can improve mobility, balance, gait, and quality of life for people with stroke or multiple sclerosis.
-
Hypnosis to improve attention and reduce fatigue in stroke, TBI, and MS
This trial tests whether adding hypnosis to standard rehab can help adults with stroke, traumatic brain injury, or multiple sclerosis improve attention and feel less fatigued.
-
Targeting the plantaris tendon during surgery to correct ankle equinus in children
This trial tests whether cutting the small plantaris tendon, together with standard calf-lengthening surgery, helps children aged 4–17 with ankle equinus walk and use their feet better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.